© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 2, 125-132,
January 15, 2003
© 2003 Oxford University Press
ARTICLE |
International Collaborative Ovarian Neoplasm Trial 1: A Randomized Trial of Adjuvant Chemotherapy in Women With Early-Stage Ovarian Cancer
International Collaborative Ovarian Neoplasm (ICON1) Collaborators1
Affiliations of Writing Committee: N. Colombo, European Institute of Oncology, Milan, Italy; D. Guthrie, M. Parmar, W. Qian, A. M. Swart, Medical Research Council Clinical Trials Unit, London, U.K.; S. Chiari, A. Lissoni, C. Bonazzi, Ospedale San Gerado, Monza, Italy; V. Torri, Mario Negri Institute, Milan; C. Williams, Cochrane Cancer Network, Oxford, U.K.
Correspondence to: Mahesh Parmar, Ph.D., Medical Research Council Clinical Trials Unit, 222 Euston Rd., London NW1 2DA, U.K. (MP{at}ctu.mrc.ac.uk).
Background: The question of whether platinum-based adjuvant chemotherapy can improve outcomes in patients with early-stage epithelial ovarian cancer is an important one. We carried out a multicenter, open randomized trial to determine whether adjuvant chemotherapy would improve overall survival and prolong recurrence-free survival in women with early-stage epithelial ovarian cancer. Methods: Between August 1991 and January 2000, 477 patients in 84 centers in five countries were randomly assigned to receive either adjuvant chemotherapy immediately following surgery (n = 241) or no adjuvant chemotherapy until clinically indicated (n = 236). Kaplan–Meier curves of overall survival and recurrence-free survival were compared using the Mantel–Cox version of the log-rank test. All statistical tests were two-sided. Results: Women who received adjuvant chemotherapy had better overall survival than women who did not (hazard ratio [HR] of 0.66, 95% confidence interval [CI] = 0.45 to 0.97; P = .03). These results translate into 5-year survival figures of 70% for women who did not receive adjuvant chemotherapy and 79% for women who did receive adjuvant chemotherapy, a difference of 9% (95% CI = 1% to 15%). Adjuvant chemotherapy also improved recurrence-free survival (HR = 0.65; 95% CI = 0.46 to 0.91; P = .01). These results translate into 5-year recurrence-free survival figures of 62% for women who did not receive adjuvant chemotherapy and 73% for women who did receive adjuvant chemotherapy, a difference of 11% (95% CI = 3% to 18%). Conclusion: These results suggest that platinum-based adjuvant chemotherapy improves survival and delays recurrence in patients with early-stage ovarian cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Nagar and S. Dobbs Management of early-stage epithelial ovarian cancer Obstet Gynaecol (Lond), October 1, 2007; 9(4): 243 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Trope and J. Kaern Adjuvant Chemotherapy for Early-Stage Ovarian Cancer: Review of the Literature J. Clin. Oncol., July 10, 2007; 25(20): 2909 - 2920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Aletti, M. M. Gallenberg, W. A. Cliby, A. Jatoi, and L. C. Hartmann Current Management Strategies for Ovarian Cancer Mayo Clin. Proc., June 1, 2007; 82(6): 751 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Goodheart, J. M. Ritchie, S. L. Rose, J. P. Fruehauf, B. R. De Young, and R. E. Buller The Relationship of Molecular Markers of p53 Function and Angiogenesis to Prognosis of Stage I Epithelial Ovarian Cancer Clin. Cancer Res., May 15, 2005; 11(10): 3733 - 3742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Penson, D. Sahani, and D. A. Bell Case 37-2004 - A 52-Year-Old Woman with Postmenopausal Bleeding and a Cystic Ovarian Mass N. Engl. J. Med., December 9, 2004; 351(24): 2531 - 2538. [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Muller, S. Millinger, H. Fiegl, G. Goebel, L. Ivarsson, A. Widschwendter, E. Muller-Holzner, C. Marth, and M. Widschwendter Analysis of Methylated Genes in Peritoneal Fluids of Ovarian Cancer Patients: A New Prognostic Tool Clin. Chem., November 1, 2004; 50(11): 2171 - 2173. [Full Text] [PDF]
|
|
|
|
|
|
R. C. Young, M. F. Brady, R. K. Nieberg, H. J. Long, A. R. Mayer, S. S. Lentz, J. Hurteau, and D. S. Alberts Adjuvant Treatment for Early Ovarian Cancer: A Randomized Phase III Trial of Intraperitoneal 32P or Intravenous Cyclophosphamide and Cisplatin--A Gynecologic Oncology Group Study J. Clin. Oncol., December 1, 2003; 21(23): 4350 - 4355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Kolomainen, R. A'Hern, F. Y. Coxon, C. Fisher, D. M. King, P. R. Blake, D. P.J. Barton, J. H. Shepherd, S. B. Kaye, and M. E. Gore Can Patients With Relapsed, Previously Untreated, Stage I Epithelial Ovarian Cancer Be Successfully Treated With Salvage Therapy? J. Clin. Oncol., August 15, 2003; 21(16): 3113 - 3118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Green Re: Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Cancer J Natl Cancer Inst, August 6, 2003; 95(15): 1169 - 1169. [Full Text] [PDF]
|
|
|
|
|
|
J. B. Trimbos and I. Vergote RESPONSE: Re: Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Cancer J Natl Cancer Inst, August 6, 2003; 95(15): 1170 - 1171. [Full Text] [PDF]
|
|
|
|
|
|
D. Guthrie RESPONSE: Re: Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Cancer J Natl Cancer Inst, August 6, 2003; 95(15): 1169 - 1170. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Navo and J. A. Smith Update on the Prevention and Treatment of Ovarian Cancer Journal of Pharmacy Practice, June 1, 2003; 16(3): 149 - 156. [Abstract] [PDF]
|
|
|
|
 |
|
 Early-Stage Ovarian Cancer: Is Adjuvant Chemotherapy Warranted? Journal Watch (General), February 7, 2003; 2003(207): 1 - 1. [Full Text]
|
|
|
|
 |
|
 S. Mayor Adjuvant chemotherapy improves survival in early ovarian cancer BMJ, January 25, 2003; 326(7382): 181 - 181. [Full Text] [PDF]
|
|
|
|
|
|
R. C. Young Early-Stage Ovarian Cancer: To Treat or Not To Treat J Natl Cancer Inst, January 15, 2003; 95(2): 94 - 95. [Full Text] [PDF]
|
|
|
|
|
|
ICON1 and EORTC-ACTION International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: Two Parallel Randomized Phase III Trials of Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Carcinoma J Natl Cancer Inst, January 15, 2003; 95(2): 105 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Trimbos, I. Vergote, G. Bolis, J. B. Vermorken, C. Mangioni, C. Madronal, M. Franchi, S. Tateo, G. Zanetta, G. Scarfone, et al. Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm Trial J Natl Cancer Inst, January 15, 2003; 95(2): 113 - 125. [Abstract] [Full Text] [PDF]
|
|